25 May 2018 - - Cambridge, Massachusetts-based genome editing company LogicBio Therapeutics, Inc. has appointed Dean Falb, Ph.D. as chief scientific officer (CSO), the company said.
Falb has more than 20 years of drug discovery and development experience. He was most recently chief technology officer and co-founder Synlogic Therapeutics, where he led the company's effort to develop engineered synthetic microbes for rare disease and oncology applications.
Prior to Synlogic, he was an entrepreneur in residence at Atlas Ventures, where he helped guide the launch of several early stage life sciences companies.
From 2005 to 2012, he served as vice president of research at Stryker Regenerative Medicine where he led the discovery and development of a portfolio of bone morphogenic protein drugs in osteoarthritis.
Falb has also held leadership positions at Praecis Pharmaceuticals, Inc., NeoGenesis Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc.
He received his doctoral degree in biochemistry and molecular biology from Harvard University. As chief scientific officer, Dr. Falb will guide research strategy and drive innovation as LogicBio advances multiple product development programmes into the clinic.
LogicBio is a genome-editing company with a mission to develop transformative medicines for life-threatening diseases.
Its GeneRide technology enables highly specific genome editing and integration of the therapeutic transgene, utilising the body's own native processes to drive durable expression.
The company is initially targeting a wide range of diseases, including early-onset conditions in young patients.